Ulcerative Keratitis in Gastrointestinal Stromal Tumor Patients Treated with Perifosine

Ophthalmology

Volumn 115, Issue 3, 2008, Pages 483-487

  Shome, Debraj ^a   Trent, Jonathan ^a   Espandar, Ladan ^a   Hatef, Elham ^a   Araujo, Dejka M ^a   Song, C Diane ^b   Kim, Stella K ^a   Esmaeli, Bita ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DEXAMETHASONE; IMATINIB; LUBRICATING AGENT; PERIFOSINE; PREDNISOLONE ACETATE; PREDNISONE; STEROID; TOBRAMYCIN;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE IRRITATION; EYE TOXICITY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KERATITIS; LACRIMATION; MALE; MEDICAL RECORD; METASTASIS; MULTIPLE CYCLE TREATMENT; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SLIT LAMP; STROMA CELL; ULCERATIVE KERATITIS; VISUAL DISORDER;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CORNEAL ULCER; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GLUCOCORTICOIDS; HUMANS; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; PHOSPHORYLCHOLINE; PIPERAZINES; PREDNISOLONE; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RETROSPECTIVE STUDIES;

EID: 39749158556     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.11.016     Document Type: Article

References (11)

1. Crul M., Rosinga H., de Klerk G.J., et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 38 (2002) 1615-1621
2. Kondapaka S.B., Singh S.S., Dasmahapatra G.P., et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2 (2003) 1093-1103
3. Croom K.F., and Perry C.M. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 63 (2003) 513-522 discussion 523-4
4. Joensuu H. Second line therapies for the treatment of gastrointestinal stromal tumor. Curr Opin Oncol 19 (2007) 353-358
5. Esmaeli B., Prieto V.G., Butler C.E., et al. Severe periorbital edema secondary to ST1571 (Gleevec). Cancer 95 (2002) 881-887
6. Fraunfelder F.W., Solomon J., Druker B.J., et al. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther 19 (2003) 371-375
7. Esmaeli B., Diba R., Ahmadi M.A., et al. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec) [letter]. Eye 18 (2004) 760-762
8. Maalouf T., Angioi K., Champigneulle J., et al. Palpebral edema secondary to treatment by a specific inhibitor of tyrosine kinase: Glivec. A case report. [in French]. J Fr Ophtalmol 27 (2004) 107-109
9. Masood I., Negi A., and Dua H.S. Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery. J Cataract Refract Surg 31 (2005) 2427-2428
10. Govind Babu K., Attili V.S., Bapsy P.P., and Anupama G. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol 27 (2007) 43-44
11. Marsh Rde W., Rocha Lima C.M., Levy D.E., et al. A phase II trial of perifosine in 1ocally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol 30 (2007) 26-31